Wall Street JournalGSK, Genmab leukemia drug fails to meet main trial goalReutersJune 27 (Reuters) – GlaxoSmithKline Plc and Genmab A/S said on Friday their cancer drug Arzerra failed to treat a type of leukemia more effectively than other drugs in a late-stage trial. Arzerra, known chemically as ofatumumab, was being tested in patients …Glaxo’s Arzerra Leukemia Drug Misses Key Target in Clinical TrialWall Street JournalGSK and Genmab announce top-line results from a Phase III study of …MarketWatchGlaxo cancer drug fails Phase 3 (GSK)Seeking Alphaall 10 news articles …Read Full Story
GSK, Genmab leukemia drug fails to meet main trial goal - Reuters
Real Estate of Cebu
